These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30278369)

  • 1. The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.
    Copson E; Shaaban AM; Maishman T; Moseley PM; McKenzie H; Bradbury J; Borley A; Brzezinska M; Chan SYT; Ching J; Cutress RI; Danial I; Dall B; Kerin M; Lowery AJ; Macpherson IR; Romics L; Sawyer E; Sharmat N; Sircar T; Vidya R; Pan Y; Rea D; Jones L; Eccles DM; Berditchevski F
    Breast; 2018 Dec; 42():133-141. PubMed ID: 30278369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory breast cancer: a single centre analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery.
    Rosso KJ; Tadros AB; Weiss A; Warneke CL; DeSnyder S; Kuerer H; Ueno NT; Stecklein SR; Woodward WA; Lucci A
    Ann Surg Oncol; 2017 Oct; 24(10):2981-2988. PubMed ID: 28766220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.
    Zhou J; Yan Y; Guo L; Ou H; Hai J; Zhang C; Wu Z; Tang L
    Saudi Med J; 2014 Nov; 35(11):1324-30. PubMed ID: 25399208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
    Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
    Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations.
    Natori A; Hayashi N; Soejima K; Deshpande GA; Takahashi O; Cristofanilli M; Ueno NT; Yamauchi H
    Clin Breast Cancer; 2013 Dec; 13(6):460-4. PubMed ID: 24084032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of CNS metastases and survival in patients with inflammatory breast cancer.
    Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
    Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
    Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
    Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
    Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
    Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
    van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
    Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.
    Matro JM; Li T; Cristofanilli M; Hughes ME; Ottesen RA; Weeks JC; Wong YN
    Clin Breast Cancer; 2015 Feb; 15(1):1-7. PubMed ID: 25034439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
    Dawood S; Merajver SD; Viens P; Vermeulen PB; Swain SM; Buchholz TA; Dirix LY; Levine PH; Lucci A; Krishnamurthy S; Robertson FM; Woodward WA; Yang WT; Ueno NT; Cristofanilli M
    Ann Oncol; 2011 Mar; 22(3):515-523. PubMed ID: 20603440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
    Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
    Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.